RELAPSED AND REFRACTORY MM WITH HIGH RISK CYTOGENETICS
Is SARCLISA + Pd appropriate for your RRMM patients?
Meet John — A patient with relapsed and refractory MM with high risk cytogenetics* and disease progression after 3L treatment
Initial treatment
- John was ineligible for ASCT and treatment was initiated with the cyclophosphamide, thalidomide, dexamethasone (CTd) regimen
- Cytogenetic analysis showed translocation t(4:14)
Disease progression
- John’s disease progressed after 1.5 years
- John received second-line treatment with the bortezomib, dexamethasone (Vd) regimen and achieved a VGPR
- One year later, John was diagnosed with disease progression after a regular follow-up with his doctor and received ixazomib, lenalidomide, dexamethasone (IxaRd) and achieved a partial response (PR)
- John had disease progression while on therapy with IxaRd
Additional patient information
- Cytogenetic risk
- High
- Bone marrow plasma cells
- 40%
- Hg
- 11 g/dL
- Multiple bone lesions
- Beta-2 microglobulin
- 4.0 µL/mL
- Renal function (CrCl)
- 80 mL/min/1.73 m2
Would John be a candidate for treatment with SARCLISA + Pd?
John would be eligible for treatment with SARCLISA + Pd1,2
Percentage of patients receiving SARCLISA + Pd in the ICARIA-MM trial with similar baseline characteristics2
